SCHEMBL7188068

SCHEMBL7188068

Cc1ccc(Cl)c(C(=O)P(=O)(C(=O)c2c(Cl)cccc2Cl)c2ccccc2)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
AKR1B10 O60218 1/20 0.38
ABCB11 O95342 1/20 0.38
TTR P02766 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
FABP2 P12104 1/20 0.38
RXRA P19793 1/20 0.38
TBXA2R P21731 1/20 0.38
NR4A1 P22736 1/20 0.38
PTGS1 P23219 1/20 0.38
PDE4A P27815 1/20 0.38
MAPK1 P28482 1/20 0.38
AKR1C3 P42330 1/20 0.38
NR4A2 P43354 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
METTL3 Q86U44 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188691 0.94 TYK2 (0.40) PTGS2KMT2AMEN1AKR1B10ABCB11
SCHEMBL7186494 0.93 TYK2 (0.38) PTGS2KMT2AMEN1AKR1B10ABCB11
SCHEMBL7180078 0.89 CA12 (0.40) PTGS2KMT2AMEN1ALDH1A1FABP4
SCHEMBL7189823 0.88 TSHR (0.41) KMT2AMEN1MAPTPTK2BTYK2
SCHEMBL7181255 0.88 MEN1 (0.37) PTGS2KMT2AMEN1AKR1B10ABCB11
SCHEMBL7187499 0.87 TYK2 (0.41) KMT2AGAAMAPTITGB1ITGA4
SCHEMBL7184834 0.87 CA12 (0.41) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL7179862 0.87 TYK2 (0.44) KMT2AGAAMAPTITGB1ITGA4
SCHEMBL7174811 0.87 TYK2 (0.44) KMT2AGAAMAPTITGB1ITGA4
SCHEMBL58730 0.86 ALDH1A1 (0.47) KMT2AMAPTPTK2BTYK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PTGS2 3909/4885KMT2A 1586/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 PTGS2 3871/4885KMT2A 956/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.